Intech Investment Management LLC Invests $95,000 in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Intech Investment Management LLC bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 13,748 shares of the company’s stock, valued at approximately $95,000.

Several other hedge funds also recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC increased its position in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics in the first quarter valued at $64,000. The Manufacturers Life Insurance Company lifted its position in Zevra Therapeutics by 15.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares during the period. Hunter Associates Investment Management LLC acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $92,000. Finally, SG Americas Securities LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at about $105,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. JMP Securities initiated coverage on Zevra Therapeutics in a research report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Finally, Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Up 1.8 %

Shares of NASDAQ ZVRA opened at $9.15 on Monday. The stock has a fifty day moving average price of $8.53 and a 200 day moving average price of $6.98. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76. The company has a market cap of $488.43 million, a P/E ratio of -4.64 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the prior year, the business earned ($0.40) EPS. Research analysts anticipate that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.